Company intelligence / Profile preview

Revivocell

Warrington, England, United Kingdom

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Revivocell offers advanced in vitro human organ models for drug discovery, focusing on predictive toxicology and efficacy testing using its proprietary NANOSTACKS technology. The company is service-oriented and does not appear to have direct therapeutic candidates in clinical pipelines[1][2][3][5].

Therapeutic areas: GastroenterologyOtherNeurology
Modalities: Organ on a chipIn vitro modelCell culture platformAI-powered analytics
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Revivocell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revivocell.

Explore the full profile